As normal cells also need the expression and activation of DNA-PK to survive IR-insult, systemic administration of DNA-PK inhibitors (DNA-PKIs) in combination with radiotherapy may exacerbate normal tissue toxicity as much as tumor toxicity. This evidence concerns the gene PRKDC and neoplasm.